David Stirling

David Stirling is the current Director at BioTheryX. David has over 25 years of experience in the pharmaceutical industry, holding various positions such as Chief Scientific Officer and Founder at Celgene and Novamedix. David has been integral in the design and development of the IMiD class of protein degrader drugs. These drugs have had a significant impact in the treatment of cancer, blood disorders, and autoimmune diseases.

David Stirling's educational career began with a B.Sc. (Honours) in Applied Microbiology from the University of Strathclyde. David then went on to earn a Ph.D. in Enzymology from the University of Warwick. Finally, they earned a Sc.D. in Pharmaceutics and Drug Design from the University of Glasgow and a D.Sc. in Pharmaceutics and Drug Design from the University of Strathclyde.